Medical News

RSS

Bankers Healthcare Group named one of Central New York's Best Places to Work

Bankers Healthcare Group, the leading provider of financial solutions for healthcare professionals, has been named one of Central New York's Best Places to Work for the third consecutive year after earning first place in 2013. This year, BHG placed third among organizations with 51 or more employees.

2 Jun 2015

Yeast could serve as a test organism for study of human obesity

A team of biologists and a mathematician have identified and characterized a network composed of 94 proteins that work together to regulate fat storage in yeast.

2 Jun 2015

Zinc levels linked to formation of kidney stone

New research on kidney stone formation reveals that zinc levels may contribute to kidney stone formation, a common urinary condition that can cause excruciating pain. The research found that zinc may be the core by which stone formation starts.

2 Jun 2015

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress.

2 Jun 2015

New UA research reveals factors that can impact aging adults' quality of life

As the world's population of older adults increases, so do conversations around successful aging -- including seniors' physical, mental and social well-being.

2 Jun 2015

Centinel Spine achieves milestone implantation of 20,000 STALIF C cervical integrated interbody devices

Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.

2 Jun 2015

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

VBL Therapeutics, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Müllerian (ovarian) cancer.

2 Jun 2015

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Researchers from the University of Liverpool have found that approximately half of patients who have an eye removed because of a form of eye cancer experience 'phantom eye syndrome.'

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

U.S. states with stronger alcohol policies have lower rates of youth drinking

A new study by Boston University and Boston Medical Center researchers reveals that U.S. states with stronger alcohol policies have lower rates of youth overall drinking and binge drinking. The study's results, published in the journal Pediatrics, further suggest that the link is largely a result of policies intended mostly for adults and their effects on reducing adult binge drinking.

2 Jun 2015

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria).

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder.

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

EIB supports research and development of new wireless hearing devices by William Demant

The European Investment Bank (EIB) is supporting the development of new wireless hearing devices and research into more effective acoustic implants by global leader William Demant Holding A/S through a EUR 110 million loan.

2 Jun 2015

New insights on strategies to treat infants with seizures

New recommendations offer insights on strategies for treating infants with seizures. In an Epilepsia report, child neurologists who are members of the International League Against Epilepsy note that intervening at the time of a febrile seizure does not alter the risk for subsequent epilepsy, and there is no evidence to support the use of antiepileptic drugs for simple febrile seizures.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Groundbreaking, combination vaccine may help beat Streptococcus A infections

Griffith University's Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections.

2 Jun 2015

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys AG today announced updated clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies.

2 Jun 2015

Medical News

Bankers Healthcare Group named one of Central New York's Best Places to Work

Yeast could serve as a test organism for study of human obesity

Zinc levels linked to formation of kidney stone

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

New UA research reveals factors that can impact aging adults' quality of life

Centinel Spine achieves milestone implantation of 20,000 STALIF C cervical integrated interbody devices

VBL Therapeutics reports positive results from VB-111 Phase 1/2a study in recurrent platinum-resistant Müllerian cancer

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

U.S. states with stronger alcohol policies have lower rates of youth drinking

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

EIB supports research and development of new wireless hearing devices by William Demant

New insights on strategies to treat infants with seizures

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Groundbreaking, combination vaccine may help beat Streptococcus A infections

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News